S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PAVM · PAVmed Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$2.39
-0.32
(-11.81%)
● At close: October 16 at 4:00:00 PM EDT
DAY'S RANGE
$2.39
$2.39
$2.39
52-WEEK RANGE
$2.39
$2.13
$28.44
What's happening
- PAVM is down 11.81% today, trading at $2.39. — Live quote
- It's trading within 3% of its 52-week low ($2.13). (Finnhub fundamentals)
- Volume today (433) is well below its 3-month average of 27,770. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.87 actual vs. $-0.48 estimated (-81.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PAVM
-66.31%
vs S&P 500
-79.09%
1-YEAR RETURN
PAVM
-85.39%
vs S&P 500
-99.95%
6-MONTH RETURN
PAVM
-75.52%
3-MONTH RETURN
PAVM
-59.75%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.87
Est. $-0.48
MISS -81.5%
2026-04-26 (Q1 2026)
$-4.42
Est. $-0.71
MISS -519.0%
2026-01-26 (Q4 2025)
$-5.52
Est. $-5.51
MISS -0.2%
2025-10-26 (Q3 2025)
$-8.70
Est. $-5.20
MISS -67.2%
Valuation Measures & Ratios
Enterprise Value4$28.9M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)159.20
Price / Book71.21
EV4 / Revenue257.69
EV4 / EBITDA0.66
Profit Margin-10794.64%
Operating Margin-26898.21%
Return on Equity (ROE8)-33.51%
Return on Assets (ROA9)-29.76%
Avg Volume (3M)27,770
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $35.8M | $123.3K | $242.4M | $9.7M | $41.7M |
| P/E | -1.58 | 0.08 | 3.67 | 0.16 | 0.73 |
| Price/Sales | 542.90 | 3.01 | 238.84 | 4.90 | 13.93 |
| Price/Book | 1.02 | 0.00 | 7.45 | 0.26 | 0.93 |
| EV/Revenue | 485.57 | -154.55 | 238.84 | 4.90 | 13.93 |
| EV/EBITDA | -1.31 | 0.28 | -9.23 | — | — |
| ROE | -64.91% | 4.06% | 203.15% | 161.52% | 127.41% |
| ROA | -56.57% | 3.53% | 173.53% | 138.11% | 108.53% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,621
Change from Prior Settlement+16.68%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 450.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-10; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -10794.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -85.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PAVM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0K | $22.0K | $5.0K | $6.0K | $8.0K | $996.0K | $979.0K | $1.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.0M | -$8.0M | -$4.8M | -$4.7M | -$5.4M | -$11.6M | -$13.7M | -$14.0M |
| Net income | -$5.4M | -$60.0K | -$5.4M | -$11.9M | $19.0M | $64.4M | -$10.8M | -$15.2M |
| EPS (diluted) | $-0.87 | $-4.42 | $-0.29 | $-22.08 | $10.10 | $1.44 | $-1.19 | $-2.62 |
| EPS (basic) | $-0.87 | $-4.42 | $-0.29 | $-22.08 | $38.26 | $6.43 | $-1.19 | $-2.62 |
| Operating margin | -$21.3K | -$36.5K | -$96.9K | -$78.6K | -$68.1K | -$1.2K | -$1.4K | -$1.4K |
| Net margin | -$16.3K | -$273 | -$107.7K | -$198.7K | $237.1K | $6.5K | -$1.1K | -$1.5K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Feb '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $40.2M | $45.4M | $38.8M | $38.1M | $43.9M | $52.8M | — | $30.7M |
| Total liabilities | $20.9M | $20.4M | $16.5M | $12.3M | $12.5M | $11.9M | — | $37.7M |
| Stockholders' equity | $35.0M | $39.5M | $34.0M | $32.5M | $37.5M | $45.0M | $2.5M | -$2.5M |
| Total current assets | $4.9M | $7.4M | $2.6M | $4.2M | $5.5M | $3.6M | — | $2.2M |
| Total current liabilities | $4.1M | $3.7M | $14.8M | $10.5M | $10.5M | $9.8M | — | $35.4M |
| Cash & equivalents | $3.8M | $6.5M | $1.5M | — | — | — | — | $1.2M |
| Accounts receivable | $16.0K | $21.0K | $15.0K | — | — | — | — | $18.0K |
| Inventory | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $73.0K | $79.0K | $77.0K | $81.0K | $100.0K | $114.0K | — | $151.0K |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $51.0K | $56.0K | $56.0K | $51.0K | $51.0K | $51.0K | — | $208.0K |
| Accounts payable | $1.1M | $983.0K | $678.0K | $342.0K | $387.0K | $369.0K | — | $657.0K |
| Accrued liabilities | $2.5M | $2.1M | $2.5M | $2.7M | $2.8M | $2.3M | — | $5.2M |
| Other current liabilities | — | — | $769.0K | — | — | — | — | $362.0K |
| Common stock & paid-in capital | $6.0K | $6.0K | $1.0K | $23.0K | $20.0K | $17.0K | — | $1.0K |
| Retained earnings | -$264.5M | -$259.0M | -$258.7M | -$256.9M | -$250.6M | -$237.3M | — | -$255.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.7M | -$2.6M | -$1.6M | -$896.0K | -$1.2M | -$1.6M | $94.0K | -$8.9M |
| Investing cash flow | -$13.0K | -$22.0K | -$14.0K | -$3.0K | -$8.0K | -$6.0K | -$4.0K | -$16.1M |
| Financing cash flow | $0 | $7.6M | $0 | -$2.0K | $2.5M | $3.1M | $330.0K | $284.0K |
| Free cash flow | -$2.7M | -$2.6M | -$1.6M | -$899.0K | -$1.2M | -$1.6M | $90.0K | -$8.9M |
| Capital expenditures | $13.0K | $22.0K | $14.0K | $3.0K | $8.0K | $6.0K | $4.0K | $6.0K |
| Depreciation & amortization | $19.0K | $20.0K | $18.0K | $22.0K | $22.0K | $43.0K | $69.0K | $238.0K |
| Share-based compensation | $917.0K | $182.0K | $615.0K | $383.0K | $162.0K | $930.0K | $4.6M | $1.9M |
| Change in accounts receivable | -$5.0K | $6.0K | $12.0K | $0 | -$7.0K | -$8.0K | $2.0K | -$203.0K |
| Change in accounts payable | $75.0K | $303.0K | $339.0K | -$47.0K | $18.0K | -$286.0K | $190.0K | $304.0K |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $71.0K | $3.0M | $2.5M | $377.0K | $500.0K |
| Gross profit | — | — | — | — | -$85.0K |
| Operating income | -$21.8M | -$44.5M | -$68.8M | -$91.1M | -$54.4M |
| Net income | $401.0K | $39.8M | -$64.2M | -$89.0M | -$50.3M |
| EPS (diluted) | $-5.63 | $14.90 | $-9.16 | $-15.03 | — |
| EPS (basic) | $-5.63 | $99.15 | $-9.16 | $-15.03 | $-0.65 |
| Operating margin | -$30.7K | -$1.5K | -$2.8K | -$24.2K | -$10.9K |
| Net margin | $565 | $1.3K | -$2.6K | -$23.6K | -$10.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $38.8M | $30.7M | $33.1M | $54.0M | $87.0M |
| Total liabilities | $16.5M | $37.7M | $57.1M | $43.0M | $7.6M |
| Stockholders' equity | $34.0M | -$2.5M | -$53.8M | -$9.7M | $61.7M |
| Total current assets | $2.6M | $2.2M | $24.5M | $43.9M | $82.6M |
| Total current liabilities | $14.8M | $35.4M | $54.2M | $41.2M | $7.6M |
| Cash & equivalents | $1.5M | $1.2M | $19.6M | $39.7M | $77.3M |
| Accounts receivable | $15.0K | $18.0K | — | — | — |
| Inventory | — | — | $278.0K | $111.0K | — |
| Property, plant & equipment | $77.0K | $151.0K | $1.8M | $2.5M | $1.6M |
| Intangible assets | — | — | $1.4M | $3.4M | $2.0M |
| Other non-current assets | $56.0K | $208.0K | $1.1M | $1.1M | $725.0K |
| Accounts payable | $678.0K | $657.0K | $1.8M | $2.7M | $3.3M |
| Accrued liabilities | $2.5M | $5.2M | $6.6M | $3.7M | $4.3M |
| Other current liabilities | $769.0K | $362.0K | $777.0K | — | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $9.0K | $6.0K | $86.0K |
| Retained earnings | -$258.7M | -$255.0M | -$294.4M | -$228.2M | -$138.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.2M | -$33.6M | -$52.0M | -$71.0M | -$40.6M |
| Investing cash flow | -$31.0K | -$16.2M | $758.0K | -$4.7M | -$3.7M |
| Financing cash flow | $5.6M | $31.3M | $31.2M | $38.2M | $104.3M |
| Free cash flow | -$5.2M | -$33.6M | -$52.3M | -$72.5M | -$42.1M |
| Capital expenditures | $31.0K | $55.0K | $242.0K | $1.5M | $1.5M |
| Depreciation & amortization | $105.0K | $1.2M | $2.9M | $2.5M | $226.0K |
| Share-based compensation | $1.7M | $6.4M | $11.1M | $19.5M | $15.0M |
| Change in accounts receivable | -$3.0K | -$43.0K | $44.0K | -$183.0K | $200.0K |
| Change in accounts payable | $24.0K | -$59.0K | -$918.0K | -$742.0K | $174.0K |
| Share repurchases | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PAVM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-02-22 to 2026-04-02
Recent transactions
- Most recent: Lee Victoria Tou-ho (Chief Medical Officer) — Grant / award of 70,000 shares on 2026-04-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lee Victoria Tou-ho | Chief Medical Officer | Grant / award | 2026-04-02 | 70,000 |
| Aklog Lishan | Chairman and CEO | Grant / award | 2026-04-02 | 350,000 |
| MCGRATH DENNIS M | President and CFO | Grant / award | 2026-04-02 | 180,000 |
| Glennon Michael J | Director | Grant / award | 2026-04-02 | 13,930 |
| Baxter Timothy E | Director | Grant / award | 2026-04-02 | 13,930 |
| White Debra | Director | Grant / award | 2026-04-02 | 13,930 |
| Sparks Ronald M | Director | Grant / award | 2026-04-02 | 13,930 |
| Agrawal Sundeep | Director | Grant / award | 2026-04-02 | 13,930 |
| Gordon Michael Adam | General Counsel | Grant / award | 2026-04-02 | 110,000 |
| O'Neil Shaun | Chief Operating Officer | Grant / award | 2026-04-02 | 110,000 |
| Harvey Joan B | Director | Grant / award | 2024-02-22 | 65,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-02 | Lee Victoria Tou-ho | Chief Medical Officer | Grant / award | 70,000 | $0.00 |
| 2026-04-02 | Aklog Lishan | Chairman and CEO | Grant / award | 350,000 | $0.00 |
| 2026-04-02 | MCGRATH DENNIS M | President and CFO | Grant / award | 180,000 | $0.00 |
| 2026-04-02 | Glennon Michael J | Director | Grant / award | 13,930 | $0.00 |
| 2026-04-02 | Baxter Timothy E | Director | Grant / award | 13,930 | $0.00 |
| 2026-04-02 | White Debra | Director | Grant / award | 13,930 | $0.00 |
| 2026-04-02 | Sparks Ronald M | Director | Grant / award | 13,930 | $0.00 |
| 2026-04-02 | Agrawal Sundeep | Director | Grant / award | 13,930 | $0.00 |
| 2026-04-02 | Gordon Michael Adam | General Counsel | Grant / award | 110,000 | $0.00 |
| 2026-04-02 | O'Neil Shaun | Chief Operating Officer | Grant / award | 110,000 | $0.00 |
| 2025-09-30 | Sparks Ronald M | Director | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | White Debra | Director | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | Baxter Timothy E | Director | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | Glennon Michael J | Director | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | Agrawal Sundeep | Director | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | Gordon Michael Adam | General Counsel | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | MCGRATH DENNIS M | President and CFO | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | Aklog Lishan | Chairman and CEO | Grant / award | 150,000 | $0.00 |
| 2025-09-30 | O'Neil Shaun | Chief Operating Officer | Grant / award | 150,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-10 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-13 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
Recent news
Headlines about PAVM (PAVmed Inc.). Links open the publisher — we don’t host full articles.
-
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Yahoo Finance · 2026-09-22 -
PAVmed Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha · 2026-08-17 -
PAVmed (PAVM) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-15 -
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing Losses and Strategic Progress ...
Yahoo Finance · 2026-08-14 -
PAVmed Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 2026-08-14 -
PAVmed targets early 2027 Veris 510(k) submission while pursuing PortIO 510(k) pathway
Seeking Alpha · 2026-08-14 -
PAVmed Inc. (PAVM) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-14 -
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-14
No headlines in this category right now — try “All”.